|
HS Code |
348608 |
| Chemical Formula | C9H6BrNS |
| Molecular Weight | 238.12 |
| Appearance | Solid (likely white or off - white powder, but color may vary based on purity) |
| Physical State At Room Temperature | Solid |
| Melting Point | Specific value would require experimental determination; typically organic bromo - thiazoles have melting points in a certain range |
| Boiling Point | Also requires experimental determination; generally higher due to the molecular structure |
| Solubility In Water | Low solubility in water (organic compound with non - polar groups) |
| Solubility In Organic Solvents | Soluble in common organic solvents like dichloromethane, chloroform, etc. due to its non - polar nature |
| Density | Experimental determination needed, but density is related to its molecular weight and packing in the solid state |
| Odor | May have a faint, characteristic organic odor |
As an accredited Thiazole, 2-Bromo-5-Phenyl- factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 250g of 2 - Bromo - 5 - phenyl - thiazole in a sealed, chemical - resistant bottle. |
| Shipping | Thiazole, 2 - Bromo - 5 - Phenyl - is shipped in well - sealed containers. These are carefully packed to prevent leakage, ensuring safe transportation by appropriate means, compliant with chemical shipping regulations. |
| Storage | 2 - Bromo - 5 - phenylthiazole should be stored in a cool, dry, well - ventilated area away from heat sources and open flames. Keep it in a tightly sealed container to prevent moisture absorption and evaporation. Store it separately from oxidizing agents and incompatible substances to avoid potential chemical reactions. Follow proper labeling and safety protocols in the storage facility. |
Manufacturing-scale batch records for a VEGFR-2/PDGFR-β dual inhibitor incorporate 2-Bromo-5-phenylthiazole as the electrophilic coupling partner in a registered starting-material synthesis. The substance is introduced at a stoichiometric ratio of 1.02 eq relative to (4-aminophenyl)boronic acid pinacol ester to ensure complete consumption of the boronate component while limiting homocoupling. Compliance is maintained under ICH Q7 Section 19.4 (GMP for API starting materials) and EMA/CHMP/CVMP/SWP/169430/2012 for carrying over into dedicated cleaning validation; the brominated impurity profile is monitored against a permitted daily exposure of ≤1.5 μg/day based on the ICH M7 additive rule for DNA-reactive mutagenic alerts. The downstream transformation is executed in a 2000 L glass-lined steel reactor (Pfaudler, with 200 rpm retreat-blade agitation) under nitrogen inertisation. A degassed mixture of tetrahydrofuran and 2.0 M aqueous potassium carbonate (3.0 eq) serves as the solvent system, heated to a jacket temperature of 65 ± 2 °C. Palladium catalysis employs 0.5 mol% [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane adduct (CAS 95464-05-4), pre-dissolved in degassed THF and injected below liquid level. After 4–6 h of intensive cross-coupling, the batch is filtered through a 0.2 μm sparkler pre-coated with Celite-545, subjected to solvent-exchange into isopropyl alcohol, and seeded with milled crystals to control the polytype purity of the final freebase. The isolated intermediate is dried in a Retsch RSD/600 double-cone dryer at 45 °C and ≤10 mbar until residual solvent complies with USP <467> Option 1. The terminal product is a maleate salt pressed into film-coated immediate-release tablets at 25 mg, 50 mg, and 100 mg dose strengths, packaged in aluminium–PVC/Aclar® cold-form blisters.What process modifications are required to maintain ≤0.5% des-bromo impurity during kilogram-scale lithiation-electrophilic addition sequences with 2-bromo-5-phenylthiazole?During the preparation of a PPARα/γ dual agonist clinical candidate, the thiazole core is elaborated through a low-temperature lithium-halogen exchange. Regulatory control is governed by ICH M7 Option 3, where a purge factor above 1×10⁴ for residual n-butyl bromide and des-bromo phenylthiazole must be demonstrated via spiking studies before the filing. The addition proportion relies on a precise 1.02 eq of n-butyllithium (2.5 M in hexanes) introduced through a jacketed dosing line at −78 °C into a solution containing 1.0 eq of the substrate in anhydrous 2-methyltetrahydrofuran. To avoid the runaway exotherm that occurs at ≥−60 °C in batch mode, the validated manufacturing process utilizes a Corning Advanced-Flow™ G1 SiC reactor with 155 mL total internal volume, operated at a flow rate ratio of 6:1 (substrate stream: n-BuLi stream) and a controlled residence time of 8–12 s, achieving a heat transfer coefficient of 1700 W/m²K. In-line ReactIR 15 ATR-FTIR at the outlet continuously tracks the disappearance of the C-Br vibration at ∼520 cm⁻¹. The resulting organolithium species is quenched in-flow with a formylpiperazine electrophile, and the α-chloroketone adduct is subsequently cyclised. The final active pharmaceutical ingredient is manufactured as a spray-dried dispersion with hydroxypropyl methylcellulose acetate succinate (HPMCAS-MG) and compressed into an extended-release matrix tablet of 45 mg label strength, tested according to USP <711> dissolution apparatus 2 at 75 rpm in pH 6.8 phosphate buffer with 0.5% sodium dodecyl sulfate. Electron-transport layer doping in solution-processed phosphorescent organic light-emitting diodes utilizes iridium(III) bis(2-phenylthiazolato-N,C²′) acetylacetonate, abbreviated Ir(bt)₂(acac). The heteroleptic complex is assembled from the cyclometalating ligand precursor 2-bromo-5-phenylthiazole, which reacts via lithium-halogen exchange and subsequent transmetallation with iridium tris(acetylacetonate). Industry compliance aligns with IEC 62321-8:2017 screening for restricted phthalates and bromide, and the finished emitter must demonstrate residual chlorine/bromine below 900 ppm per RoHS 2011/65/EU Annex II limits when the compound is considered a homogeneous material inside a display assembly. The ligand-to-iridium molar ratio is maintained at 2.3:1, where the slight excess of thiazole compensates for irreversible protonolysis during cyclometallation. The reaction is performed in a 5-L double-walled borosilicate reactor containing degassed ethylene glycol monoethyl ether and 2.0 eq of sodium carbonate, heated at 110 °C for 24 h under argon overpressure. After silica-gel chromatography in a Flash 150i Biotage unit, the crude complex undergoes gradient sublimation in a Creaphys™ four-zone train with a base pressure below 1×10⁻⁶ hPa, yielding a fac-isomer of >99.9% purity as confirmed by UHPLC with a charged aerosol detector. This emitter is co-evaporated with a conductive host in a vacuum thermal evaporation source at a deposition rate of 0.2 nm/s onto a pre-patterned indium tin oxide backplane to form the emissive layer of an AMOLED display with a pixel density above 440 ppi.
Agitation Rate Control When Scaling from a 5-Liter Round-Bottomed Flask to a 100-Liter Glass-Lined CSTR for Thiazolecarboxamide Fungicide ConjugationIn the synthesis of a benzothiadiazole-type systemic acquired resistance inducer, the key convergent step couples 2-bromo-5-phenylthiazole-derived carboxylic acid with a substituted 2-aminobenzothiadiazole. The formulation design adheres to FAO Specification 483/TC for technical-grate purity, requiring ≥98.0% active ingredient content and a single unknown impurity ≤0.2% per CIPAC 1 MT 1 gravimetric assay. The coupling employs a 1.0 eq addition of the carboxylic acid activated in situ with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC·HCl, 1.05 eq) and hydroxybenzotriazole hydrate (HOBt·H₂O, 0.1 eq) in dimethylformamide at 0–5 °C, with the progress monitored by UPLC at 254 nm. Scaling from a 5-L round-bottomed flask to a 100-L Pfaudler CSTR demanded that the tip speed remain constant at 1.8 m/s, achieved by reducing the pitch-blade impeller speed from 350 rpm to 125 rpm, preventing shear-induced racemization of the chiral sulfoxide side-chain. After a 12 h reaction, the mixture is quenched into ice-water, and the crude amide is purified via slurry-to-slurry washing with 0.1 M HCl and 5% sodium bicarbonate. The final technical material is micronized in an Alpine Jet Mill AS 200 to a particle size distribution of D₅₀ ≤ 3.0 μm and formulated as a 500 g/L aqueous suspension concentrate using an ethoxylated tristyrylphenol phosphate ester dispersant, packaged in internally lacquered 20-L HDPE pails compliant with UN 31HA1/Y combination packaging. If a Buchwald-Hartwig N-arylation is executed with 2-bromo-5-phenylthiazole and a sterically demanding 2,6-diisopropylaniline within an oxygen-depleted atmosphere, the target product is a key intermediate for a calcitonin gene-related peptide receptor antagonist. Compliance with ICH Q3D Elemental Impurities Guideline imposes a palladium limit of ≤10 μg/g in the drug substance, dictating the catalyst loading. The reaction proceeds at an amine-to-thiazole ratio of 1.0:1.0, with a catalytic system composed of tris(dibenzylideneacetone)dipalladium(0) (0.2 mol%) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos, 0.4 mol%). Sodium tert-butoxide (1.4 eq) is dispersed in anhydrous toluene under a controlled headspace purge of <0.1% oxygen achieved by three vacuum-argon cycles. The 100-L glass-lined reactor is charged and maintained at an internal temperature of 80 °C for 18 h, during which in-process controls by SFC-MS track the disappearance of the bromothiazole precursor. Upon completion, the slurry is filtered through a plug of Flash-Chrom 60M silica and treated with 2.0 eq of thiol-functionalized silica scavenger (Silicycle SiliaMetS® Thio) agitated for 6 h at 55 °C to reduce residual Pd. After crystallization from heptane/isopropyl acetate, the N-arylated intermediate is isolated in 97.5% area purity and converted to a hydrochloride salt for an orally disintegrating tablet (ODT) designed for veterinary neuropathic pain management, with a disintegration time of ≤30 s as per USP <701>.Radiopharmaceutical production of ¹⁸F-labeled 2-(4-fluorophenyl)thiazole derivatives for tau protein aggregate imaging in Alzheimer’s disease relies on the nucleophilic aromatic substitution reactivity of 2-bromo-5-phenylthiazole under anhydrous conditions. The precursor synthesis batch is governed by 21 CFR 212 cGMP for positron emission tomography drugs, and the final injectable formulation must pass a USP <823> sterility test with a 14-day incubation, along with LAL endotoxin ≤2.5 EU/mL. For each production run executed in a GE TRACERlab FX N Pro automated synthesis module, 2.0 mg of the brominated thiazole precursor dissolved in 0.4 mL anhydrous dimethyl sulfoxide is added to the dried ¹⁸Ffluoride-Kryptofix® 2.2.2/potassium carbonate complex. The radiochemical conversion is conducted at 100 °C for 15 min in a sealed 5-mL V-vial, achieving a molar activity exceeding 120 GBq/μmol. Semi-preparative HPLC purification uses a Luna C18(2) 10 μm, 250×10 mm column with a mobile phase of 45% acetonitrile in 0.1% phosphoric acid at pH 3.5, isolating the ¹⁸F-thiazole product with a radiochemical purity >99.0%. The collected fraction is diluted, trapped on a C18 Sep-Pak, eluted with ethanol, and formulated in 0.9% saline containing ≤10% ethanol to a final activity concentration of 300–500 MBq/mL. The terminal product is dispensed into a 15-mL Type I borosilicate glass vial with a chlorobutyl rubber stopper, and total synthesis time from end-of-bombardment to release does not exceed 65 min.
|
Competitive Thiazole, 2-Bromo-5-Phenyl- prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Parameter | 2-Bromo-5-phenylthiazole | 2-Chloro-5-phenylthiazole | 2-Iodo-5-phenylthiazole |
|---|---|---|---|
| CAS RN | 7048-06-8 | 3464-41-9 | 142493-69-2 |
| Appearance (25 °C) | pale yellow low-melt solid | colourless oil | yellow crystalline solid |
| Melting range (DSC onset) (°C) | 50–54 | \\< −20 | 78–82 |
| Assay (GC-FID, area%) | ≥ 98.5 | ≥ 97.0 | ≥ 97.0 (HPLC) |
| Relative Suzuki ratea | 1.0 (ref) | 0.09 | 1.4 |
| Halogen content (%) | Br 33.3 | Cl 18.1 | I 47.1 |
| Recommended storage (°C) | 2–8, under argon | 2–8, under argon | −20, dark, under argon |
| Standard / Regulation | Applicable scope | Test method / evidence |
|---|---|---|
| REACH (EC) No 1907/2006 | ≥ 1 t/a registered tonnage | Registration dossier including physicochemical, toxicological endpoints |
| FDA 21 CFR 210/211 | Current Good Manufacturing Practice for finished pharmaceuticals | Vendor qualification audit, residual solvent analysis |
| ICH Q3D | Elemental impurities | ICP-MS for 1A, 2A, 2B classes; Pd, Cu, Fe routinely monitored |
| ASTM D4054-22 | Aviation turbine fuel additive qualification (if used as anti-corrosion precursor) | Thermal stability (JFTOT), material compatibility |
| EU 2019/1021 | Persistent organic pollutants | Certification of non-intentional addition of listed brominated flame retardants |
| ISO 9001:2015 | Quality management systems | Full batch traceability, out-of-spec handling procedures |